Breathing New Life Into the NSCLC Pipeline

The next two years may well see an explosion of FDA approvals for non-small cell lung cancer (NSCLC), with some of the drugs being first-in-class and/or best-in-class. If even a few of these agents make it through the regulatory gauntlet, clinicians will have a powerful new set of therapeutics to combat this challenging malignancy, a pharmaceutical industry analyst predicted at the NASP 2024 Annual Meeting & Expo, in Nashville, Tenn. 

The coming wave of NSCLC approvals was one of many